United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Pfizer Inc will supply the United States with 100 million additional doses of its COVID-19 vaccine by July next year, the U.S. drugmaker said on Wednesday.

Pfizer to supply U.S. with 100 million more COVID-19 shots by July

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies' COVID-19 Vaccine from production facilities in the U.S. This agreement brings the total number of doses to be delivered to the U.S. to 200 million. The companies expect to deliver the full 200 million doses to Operation Warp Speed (OWS) by July 31, 2021. Consistent with the origi

Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

Pfizer is reportedly close to striking a deal with the Trump administration to supply tens of million more doses of its COVID-19 vaccine to the US in 2021, people familiar with the discussions told The New York Times Tuesday. The US government wants 100 million additional doses of Pfizer and its German partner BioNTech's vaccine between April to June, the Times reported. The drugmaker has said it could supply 70 million doses, the people said, provided it gets better access to manufacturing supplies through the Defense Production Act.

Pfizer and the Trump administration are reportedly close to agreeing 70 million extra vaccine doses for next year to plug a potentially massive shortfall in the US

Moderna

Should You Worry About This Side Effect to Moderna's and Pfizer's COVID Vaccines?

Throw Growth Aside and See Pfizer Stock as Top Dividend and Cash Flow Play

Another deal with Pfizer would move the nation closer to the goal of vaccinating all Americans.

US close on deal with Pfizer for millions more vaccine doses

LUND, Sweden, Dec. 23, 2020 /PRNewswire/ -- BioInvent International AB (OMXS: BINV ), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that Pfizer Inc. ("Pfizer") (NYSE: PFE) has...

BioInvent receives $3 million payment related to selection of antibodies under collaboration with Pfizer Inc.

Pfizer Inc (NYSE: PFE) is nearing a deal with the outgoing President Donald Trump's administration to supply 100 million doses of its coronavirus vaccine to the United States, the Wall Street Journal reported Tuesday. What Happened: The U.S. government would pay Pfizer $2 billion as per the terms of the deal, under consideration, and the drugmaker would provide the vaccine doses by July, people familiar with the matter told the Journal.

Pfizer Nears Deal To Supply Another 100M COVID-19 Vaccine Doses To US By July

The government had the opportunity to secure 600 million doses under an agreement signed in July.

Report: Trump Administration Nears Deal For Additional Pfizer Vaccine Doses

The U.S. government is close to a deal with Pfizer for up to an additional 100 million doses of its coronavirus vaccine, a source told CNBC's Meg Tirrell on Tuesday.

Pfizer nears deal with U.S. government for more Covid vaccine doses, source says

Argan

Greif

Marsh & McLennan

Prestige Brands Holdings

Markets sharply reversed during yesterday's trading session. However, the indices ended the day largely mixed.

Top Stocks To Buy Today As Markets Trade Mixed After Yesterday's Session

Even with the relief brought by the conditional approval of two coronavirus vaccines, a more virulent and contagious variant of the virus in the U.K. has emerged.  Pfizer Inc. (NYSE: PFE), with its German partner BioNTech SE – ADR (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) are the two companies that have received approval for emergency use of their respective investigational vaccines.

Moderna, Pfizer Testing Coronavirus Vaccine Against New Strain

Merck

Novartis

3 Large Drugmakers Set to Rule the Sector in 2021

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 2, 2021. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Fourth Quarter and Full Year 2020 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/

Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts

Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate is the first COVID-19 vaccine to be granted conditional authorization in Europe.

Pfizer/BioNTech COVID-19 Vaccine Gets Authorization in Europe

BioNTech's CEO said on Tuesday that while it is currently unclear whether the vaccine can protect against the new U.K. strain, it is “highly likely” the shot can protect against new variants.

Pfizer-BioNTech, Moderna Test Vaccines Against New Covid-19 Variant Spreading Across U.K.

It might seem like it, based on the stock's recent performance.

Is Pfizer's COVID Vaccine Growth Story Already Over?

Intel

Johnson & Johnson

MDU Resources Group

J. M. Smucker

Vanguard High Dividend Yield ETF

My dividend stock portfolio was burnt by dividend cuts and lost over $800+ in forward dividend income. Therefore, I was ready to get back to basics and acquire more shares in the best quality dividend stocks out there. My dividend stock purchases of VYM totaled $1,307.79, acquiring 15 total shares. This added $41.10 in forward dividend income. I will continue this going forward, 3 shares per week.

Dividend Stock Purchase: Lanny's November 2020 Summary

The Pfizer-BioNTech vaccine has landed in the tiny-island nation after it was approved for distribution last week.

Singapore is first Asian country to receive batch of Pfizer's Covid-19 vaccine

Ugur Sahin, CEO of BioNTech SE (NASDAQ: BNTX) — the German partner of Pfizer Inc (NYSE: PFE) — expressed confidence that two companies' jointly-developed vaccine is effective against a new mutation of COVID-19, Reuters reported Monday.  What Happened: Sahin told Germany's Bild TV that BioNTech would look into the mutation that has emerged out of the United Kingdom in the coming days and viewed the matter “with a degree of soberness,” as per Reuters.

Pfizer Partner BioNTech Confident Vaccine Effective Against UK Mutant COVID-19 Strain

BNT162b2 gets another green light from a top healthcare regulator.

Pfizer and BioNTech's Coronavirus Vaccine Approved in Europe

The U.S. is planning a study to find out why some people have suffered from allergic reactions after receiving a Covid vaccine, an NIAID official told CNBC.

U.S. plans to study allergic reactions from Pfizer's Covid vaccine

Shares of Pfizer Inc. were down 1.1% and BioNTech SE shares were up 1.2% in trading on Monday after the companies said their COVID-19 vaccine has been recommended for authorization in the European Union. The Committee for Medicinal Products for Human Use made the recommendation, and the European Commission is expected to review it and make a final decision in the "near future.

E.U. committee recommends authorization of BioNTech and Pfizer's coronavirus vaccine

Microsoft

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Mixed sentiment is once again the theme. On one hand, a stimulus package finally passed and a second coronavirus vaccine is on its way.

Trending Stocks For This Week As Markets Remain Sensitive To News

The European Commission gave approval on Monday for the use of the COVID-19 vaccine jointly developed by U.S. company Pfizer and its German partner BioNTech, the final step to allowing Europe to start inoculations within a week.

News for Pfizer Stock (PFE)